Vol. 9, No. 3
2009

Selected Topics in Respiratory and Allergic Diseases

Contributors

Disclosures

Introduction

[PDF]

From the Page to the Clinic: Implementing New National Asthma Education and Prevention Program Guidelines

Gary S. Rachelefsky, MD
[PDF]

Clinical Importance of Identifying Immunoglobulin E-Mediated Disease in Patients With Asthma

Thomas B. Casale, MD
Richard J. Martin, MD
[PDF]

A 12-Year-Old Student Athlete With Exercise-Induced Bronchospasm: Getting Jenny B. Back on Track

A Case 360°™ Patient Presentation
Giselle Mosnaim, MD, MS
[PDF]

Using Long-Acting β₂-Agonists Safely: What Will Be the Impact of the US Food and Drug Administration’s Panel Recommendations?

Brian A. Smart, MD
[PDF]

Inhaled Anticholinergics and the Long-Term Treatment of Chronic Obstructive Pulmonary Disease: Weighing Benefits and Risks

D. Kyle Hogarth, MD, FCCP
Terry A. Jacobson, MD, FACP, FAHA

[PDF]

Hydrofluoroalkane Mandate in Effect January 1, 2009: Switch From Chlorofluorocarbonto Hydrofluoroalkane-Propelled Inhalers Requires Active Transition

Stephen Peters, MD, PhD

[PDF]

Should Clinicians Routinely Determine Rhinitis Subtype on Initial Diagnosis and Evaluation? A Debate Among Experts

Martin Quan, MD
Thomas B. Casale, MD
Michael S. Blaiss, MD

[PDF]

Hydrofluoroalkane Tear-Out Sheet

The articles published in this issue were submitted by the Respiratory & Allergic Disease Foundation